EBOS GROUP LIMITED (EBO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBO

EBO - EBOS GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.68
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$35.00

21 Feb
2025

0.090

OPEN

$35.37

0.26%

HIGH

$35.37

112,890

LOW

$34.58

TARGET
$35.853 2.4% upside
Franking for last dividend paid out: 49%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
EBO: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 141.3 137.1 xxx
DPS (cps) xxx N/A 107.3 xxx
EPS Growth xxx 6.3% - 3.0% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 25.5 xxx
Dividend Yield xxx N/A 3.1% xxx
Div Pay Ratio(%) xxx N/A 78.2% xxx

Dividend yield today if purchased 3 years ago: 1.47%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.59

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/08 - ex-div 49.71c (franking 49%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx141.3
DPS All xxxxxxxxxxxxxxx114.5
Sales/Revenue xxxxxxxxxxxxxxx13,189.1 M
Book Value Per Share xxxxxxxxxxxxxxx1,268.4
Net Operating Cash Flow xxxxxxxxxxxxxxx348.2 M
Net Profit Margin xxxxxxxxxxxxxxx2.06 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx11.12 %
Return on Invested Capital xxxxxxxxxxxxxxx7.88 %
Return on Assets xxxxxxxxxxxxxxx4.12 %
Return on Equity xxxxxxxxxxxxxxx11.12 %
Return on Total Capital xxxxxxxxxxxxxxx12.64 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx96.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx823 M
Long Term Debt xxxxxxxxxxxxxxx820 M
Total Debt xxxxxxxxxxxxxxx1,643 M
Goodwill - Gross xxxxxxxxxxxxxxx2,068 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx217 M
Price To Book Value xxxxxxxxxxxxxxx2.32

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx118.8 M
Capex % of Sales xxxxxxxxxxxxxxx0.90 %
Cost of Goods Sold xxxxxxxxxxxxxxx12,232 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx474 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx89 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.4

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

5

xxxxxxxxx xx xxxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

20/02/2025

2

Downgrade to Accumulate from Buy

$37.00

5.71%

Ebos Group produced a first half result that was in line with forecasts. Ord Minnett observes the business is executing well on its revenue and cost initiatives and now forecasts FY25 EBITDA of $592m and net profit of $269m.

The business is "quality", the broker adds and should emerge from the transition period in FY25 with a well-established and diversified business model. Target rises to $37.00 from $35.50. Rating pulls back to Accumulate from Buy after the recent re-rating.

FORECAST
Ord Minnett forecasts a full year FY25 dividend of 107.30 cents and EPS of 137.40 cents.
Ord Minnett forecasts a full year FY26 dividend of 118.80 cents and EPS of 158.40 cents.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

20/02/2025

2

Overweight

-

-

Ebos Group navigated the loss of Chemist Warehouse Australian (CWA) contract, Jarden highlights, with 1H25 pharmacy revenue growth an impressive 12% y/y, and group revenue up 9.5%. Cashflows were strong, reflecting the unwind of the CWA inventories, which was used to fund investments and maintain the interim dividend.

The group maintained FY25 EBITDA guidance at $575-600m, with the broker noting key near-term growth drivers are on track or ahead of plan for new pharmacy wholesale wins. 

The broker left FY25-26 EBITDA forecasts largely unchanged and made modest downgrades at EPS level to reflect higher capital investment and net interest expense. Overweight rating and NZ$41.5 target price.

FORECAST
Jarden forecasts a full year FY25 dividend of 107.00 cents and EPS of 141.00 cents.
Jarden forecasts a full year FY26 dividend of 111.00 cents and EPS of 159.00 cents.
Access Extra Coverage Research History >

EBO STOCK CHART

FNArena News on EBO

1
FNArena Corporate Results Monitor – 22-02-2025

Feb 22 2025 - Australia
2
Rudi’s View: Best Ideas & Conviction Calls

Feb 20 2025 - Rudi's View
3
FNArena Corporate Results Monitor – 20-02-2025

Feb 20 2025 - Australia
4
Rudi’s View: AGL Energy, Bega Cheese, BRG, Harvey Norman, Imdex & Superloop

Feb 06 2025 - Rudi's View
5
Rudi’s View: Cochlear, Guzman y Gomez, SiteMinder, Wesfarmers & Xero

Jan 30 2025 - Rudi's View

Latest Healthcare services News

1
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
2
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
3
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
4
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
5
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
6
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
7
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
8
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
9
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
10
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia